National Cancer Advisory Board

National Cancer Advisory Board. The National Cancer Advisory Board is a presidentially appointed federal advisory committee that provides guidance to the National Cancer Institute, a component of the National Institutes of Health. Established by the National Cancer Act of 1971, the board plays a critical role in reviewing and recommending approval for major programs and initiatives within the national cancer research portfolio. Its members, comprising leading scientists, physicians, and public representatives, advise the Secretary of Health and Human Services and the Director of the National Cancer Institute on a wide range of policy and scientific matters.

History and establishment

The board was created by the landmark National Cancer Act of 1971, which was signed into law by President Richard Nixon and is often referred to as the "War on Cancer" legislation. This act transformed the National Cancer Institute by providing it with enhanced budgetary authority and a direct reporting line to the President of the United States. It replaced the previous National Advisory Cancer Council, expanding its membership and formalizing its advisory role within the federal government's cancer research enterprise. The legislation was championed by figures like Senator Jacob Javits and activist Mary Lasker, who advocated for a more aggressive national effort against the disease.

Membership and appointment process

The board is composed of up to eighteen members appointed by the President of the United States, in addition to twelve non-voting members representing other federal agencies. Appointed members include distinguished leaders from fields such as basic biomedical research, clinical oncology, public health, and law, as well as representatives from the general public. The appointment process involves nominations from the scientific community and recommendations from the Director of the National Cancer Institute, with final selections made by the White House. Members typically serve overlapping six-year terms, ensuring continuity of expertise, and the board is led by a chairperson elected from among its voting members.

Roles and responsibilities

Its primary statutory responsibility is to review and make recommendations on grant applications and cooperative agreements following their initial technical review by scientific study sections. The board also provides second-level review for research project grants, program project grants, and specialized center grants before their final approval and funding. Beyond grant review, it advises the Director of the National Cancer Institute on the institute's policies, programs, and scientific priorities, including the development of the National Cancer Plan. Furthermore, the board submits an annual report on its activities directly to the Secretary of Health and Human Services and the President of the United States.

Relationship to the National Cancer Institute

The board operates as a key external advisory body to the National Cancer Institute, providing independent oversight and counsel that is integral to the institute's governance structure. While the National Cancer Institute Director retains ultimate authority for research funding decisions, the board's recommendations carry significant weight in shaping the national cancer research agenda. It works in concert with other advisory groups, such as the President's Cancer Panel and the National Institutes of Health Council of Councils, to ensure a coordinated approach to cancer policy. The board's meetings and deliberations are closely aligned with the strategic planning efforts of the National Cancer Institute Office of the Director.

Key activities and impact

The board conducts quarterly public meetings where it reviews scientific progress, hears reports from National Cancer Institute leadership, and deliberates on emerging issues in cancer research and care. It has played a pivotal role in advising on major initiatives, including the launch of the Cancer Moonshot, the expansion of the National Clinical Trials Network, and the establishment of programs focused on health disparities like the Center to Reduce Cancer Health Disparities. Through its review of thousands of grant applications, the board has directly influenced the direction of funding for groundbreaking research in areas such as immunotherapy, genomics, and cancer prevention. Its ongoing evaluations help ensure that the national investment in cancer research through the National Institutes of Health is both scientifically meritorious and aligned with public health needs.

Category:United States Department of Health and Human Services Category:National Cancer Institute Category:Health-related professional associations in the United States